Business Wire

ADVA

27.4.2021 09:02:12 CEST | Business Wire | Press release

Share
ADVA launches market’s first compact grandmaster clock with multi-band GNSS receiver

ADVA (FSE: ADV) today launched its OSA 5405-MB , the industry’s first ultra-compact outdoor PTP grandmaster clock with multi-band GNSS receiver and integrated antenna. Part of the OSA 5405 Series of smart synchronization devices for indoor or outdoor deployment, the OSA 5405-MB ensures timing accuracy by eliminating the impact of ionospheric delay variation. This empowers communication service providers (CSPs) and enterprises to deliver the nanosecond precision needed for 5G fronthaul and other emerging time-sensitive applications. The multi-band GNSS receiver and integrated antenna enable the OSA 5405-MB to meet PRTC-B accuracy requirements (+/-40nsec) even in challenging conditions. For the first time, the technology is available in an edge timing device with minimal footprint, helping operators achieve unprecedented accuracy and reliability as they roll out wide-spread small cell networks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005060/en/

“Our multi-band, multi-constellation GNSS receiver provides an extremely cost-efficient way to achieve PRTC-B UTC-traceable network timing with the levels of accuracy needed for next-generation use cases. By adding this technology to our versatile, small-form-factor OSA 5405 Series, we’re offering a route to precision synchronization at the network access without significant investment,” said Gil Biran, general manager, Oscilloquartz, ADVA. “A ruggedized design and minimal visibility make our OSA 5405-MB easy to install in almost any outdoor location. With the power to compensate for ionospheric delay variations and provide resilience against jamming and spoofing, our compact edge solution really is the key to 5G synchronization.”

The OSA 5405 Series is a uniquely versatile timing solution ideal for deployment deep in urban canyons, precisely where the most advanced end applications require stringent synchronization. With its small form factor, the OSA 5405-I indoor variant can be positioned on windows to avoid multipath signal interference. Offering both electrical and optical interfaces and featuring cost-effective Ethernet cabling, the OSA 5405 Series avoids the archaic and expensive RF feeds of traditional GNSS installations by integrating an antenna, GNSS receiver and PTP grandmaster in a single device.

Now with multi-band GNSS technology, the OSA 5405-MB also protects against timing inaccuracies caused by ionospheric disturbance. By receiving GNSS signals in two frequency bands and using the differences between them to calculate and compensate for delay variation, the OSA 5405-MB eliminates inaccuracy and ensures ultra-precise synchronization whatever the space weather conditions. It can also work with up to four concurrent GNSS constellations (GPS, GALILEO, GLONASS and BEIDOU), increasing the number of observable satellites in urban canyons. A comprehensive set of Syncjack™ PTP and GNSS jamming and spoofing monitoring features in combination with ADVA’s Ensemble Controller and Sync Director assures highest synchronization quality and provides transparency for simple operation of even very large synchronization networks. The OSA 5405-MB also offers network-delivered timing backup to further mitigate GNSS vulnerabilities and make synchronization more robust and resilient.

“Highly accurate timing is becoming more critical every year. In CSP infrastructure, power utilities, broadcast and enterprise networks across most industries, precision synchronization that meets tight PRTC-B specifications is essential. The OSA 5405-MB is capable of providing different PTP profiles as well as NTP directly out of the smart antenna with no compromise on accuracy,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “With its multi-band receiver, our new OSA 5405-MB delivers PRTC-B levels of synchronization accuracy. Small, lightweight, low-power and versatile, it can be deployed almost anywhere and will perform perfectly even under extreme conditions. What’s more, its Syncjack™ PTP and GNSS assurance capabilities ensure accurate, real-time monitoring of timing quality.”

Further information on the OSA 5405-MB is available in these slides: https://adva.li/osa-5405-mb-slides .


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye